Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00032929
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2002-04-05
Brief Title:
Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Double-Blind Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence
Detailed Description:
The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System STS in reducing cocaine use in subjects with cocaine dependence It is hypothesized that selegiline treatment compared to placebo will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine BE
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None